Applications of Dual Centrifugation Technology in Pharmaceutics

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3408

Special Issue Editor


E-Mail Website
Guest Editor
1. Pharmaceutical Institute, University of Freiburg, Freiburg, Germany
2. Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany
Interests: dual centrifugation; liposomes; polymersomes; LNP; nanomilling; lipid-turnover

Special Issue Information

Dear Colleagues,

Dual centrifugation (DC) is a new and innovative in-vial homogenization and in-vial milling technique for preparing liposomes and other lipid nanoparticles, including emulsions, solid lipid nanoparticles, as well as polymersomes and nanocrystals. Significant improvements in equipment technology have been achieved during the last decade, so that DC is now on its way to becoming the quasi-standard for the simple, fast, and sterile production of lipid nanoparticles and nanocrystals in small- and medium-batch sizes, including the possibility of conducting simple and fast formulation screening or bed-side preparations of therapeutic nanoparticles.

In light of this, we have noticed a strong increase in interest in dual centrifugation in recent years. Thus, the journal Pharmaceuticals invites both reviews and original articles that highlight the challenges and opportunities of using this new method in drug formulation development. Potential topics include dual centrifugation (general aspects), the DC preparation of liposomes, solid lipid nanoparticles, emulsions, polymersomes, and nanocrystals, including their characterization, biophysical properties, and use in biological in vivo and in vitro studies. The collection of manuscripts will be published in a Special Issue of the journal.

Dr. Ulrich Massing
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dual centrifugation
  • in-vial homogenization
  • in-vial nanomilling
  • liposomes
  • bedside preparation
  • solid lipid nanoparticles
  • emulsions
  • polymersomes
  • nanocrystals

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 3217 KiB  
Article
Solubility of Poorly Soluble Drugs in Phosphatidylcholine-Based Drug Delivery Systems: Comparison of the Loading Capacity in the Bulk Formulation and Its Dispersed State
by Linda Grüne and Heike Bunjes
Pharmaceuticals 2024, 17(3), 400; https://doi.org/10.3390/ph17030400 - 21 Mar 2024
Viewed by 986
Abstract
The aim of this study was to determine the drug loading capacity of phosphatidylcholine-based formulations for four poorly water-soluble drug substances (clofazimine, fenofibrate, artemether, cannabidiol). Two self-dispersing lipid formulations were investigated, which consisted of soybean phospholipids, medium-chain triglycerides and ethanol with a different [...] Read more.
The aim of this study was to determine the drug loading capacity of phosphatidylcholine-based formulations for four poorly water-soluble drug substances (clofazimine, fenofibrate, artemether, cannabidiol). Two self-dispersing lipid formulations were investigated, which consisted of soybean phospholipids, medium-chain triglycerides and ethanol with a different phospholipid–oil ratio. The direct loading of the bulk formulation was conducted with dual centrifugation, which proved to be a suitable method for screening experiments with the highly viscous formulations. To estimate possible precipitation after dispersion in the gastrointestinal fluids, the solubility of the drugs was investigated in the dispersed formulations. For this purpose, nanodispersions were prepared from the bulk formulations via high pressure homogenization and subsequently subjected to passive loading. A newly developed HPLC method with Charged Aerosol Detection allowed a simultaneous evaluation of the content of soybean lecithin and medium-chain triglycerides in the nanodispersions. When comparing the two phosphatidylcholine-based formulations, a high content of oil was advantageous with regard to a high loading capacity. Drug substances with melting points below 150 °C exhibited a high solubility in the phospholipid-based formulations. A surprisingly high solubility was observed for artemether and cannabidiol with up to 13.0% and 33.3% drug loaded to the formulations, respectively. In the dispersions, a similar solubility as in the bulk formulations was obtained for fenofibrate and cannabidiol. Clofazimine yielded a higher loading result in the nanodispersions than in the bulk formulation. Full article
(This article belongs to the Special Issue Applications of Dual Centrifugation Technology in Pharmaceutics)
Show Figures

Figure 1

Review

Jump to: Research

29 pages, 2641 KiB  
Review
Preparation of Nanosized Pharmaceutical Formulations by Dual Centrifugation
by Jonas K. Koehler, Stefanie Schmager, Valentin Bender, Denise Steiner and Ulrich Massing
Pharmaceuticals 2023, 16(11), 1519; https://doi.org/10.3390/ph16111519 - 25 Oct 2023
Cited by 4 | Viewed by 1983
Abstract
Dual centrifugation (DC) is an innovative in-vial homogenization and in-vial nanomilling technique that has been in use for the preparation of liposomes for more than one decade. Since then, DC has continuously been developed for preparing various liposomes and other lipid nanoparticles including [...] Read more.
Dual centrifugation (DC) is an innovative in-vial homogenization and in-vial nanomilling technique that has been in use for the preparation of liposomes for more than one decade. Since then, DC has continuously been developed for preparing various liposomes and other lipid nanoparticles including emulsions and solid lipid nanoparticles (SLNs) as well as polymersomes and nanocrystals. Improvements in equipment technology have been achieved over the past decade, so that DC is now on its way to becoming the quasi-standard for the simple, fast, and aseptic production of lipid nanoparticles and nanocrystals in small and medium batch sizes, including the possibility of simple and fast formulation screening or bedside preparations of therapeutic nanoparticles. More than 68 publications in which DC was used to produce nanoparticles have appeared since then, justifying an initial review of the use of DC for pharmaceutical nanotechnology. Full article
(This article belongs to the Special Issue Applications of Dual Centrifugation Technology in Pharmaceutics)
Show Figures

Graphical abstract

Back to TopTop